血小板疾病和药物治疗策略
Zhao Zhang1, Xianghui Zhou1, Xiyuan Fang1
1Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Thrombosis and haemostasis
|March 19, 2025
概括
本综述探讨了血小板的产生,包括造血干细胞和巨核细胞. 它总结了血小板乱,如血小板缺血和血小板和他们的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 血小板是参与血液静止和免疫的重要血液细胞.
- 血小板的产生涉及到造血干细胞分化为巨核细胞,释放在循环中成熟的血小板.
- 血小板数量障碍是由影响生产,清除和分布的复杂调节因素引起的.
研究的目的:
- 审查血小板生产的复杂调节.
- 总结一下常见的血小板数量障碍:血小板缺血和血小板化.
- 巩固各种血小板疾病的药物治疗策略的临床证据.
主要方法:
- 关于血小板生产和疾病的科学研究的文献综述.
- 对有关血小板缺血和血小板瘤的临床数据的分析.
- 关于治疗血小板失调的治疗干预措施的信息综合.
主要成果:
- 详细检查了血小板生物发生的多步骤过程.
- 导致血小板数量低 (血小板缺血) 或高 (血小板细胞增多) 的疾病的分类和描述.
- 目前适合特定血小板疾病背景的药理学方法的概述.
结论:
- 血小板的生产是一个严格规范的过程,容易受到各种干扰.
- 血小板缺血和血小板化代表着具有不同病因的重大临床挑战.
- 血小板疾病的有效管理需要了解潜在的机制,并应用基于证据的治疗策略.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
441
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
441
Disorders of Hemostasis
673
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
673
Formation of the Platelet Plug
3.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
Structure and Function of Platelets
931
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
931
Clot Retraction and Fibrinolysis
3.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.1K


